Press Releases Telix Pharmaceuticals Limited

Stocks

TLX

AU000000TLX2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:12:56 12/06/2026 BST			5-day change	1st Jan Change
13.60 ^AUD	+0.97%		+2.18%	+21.43%

06-03	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%	MT
06-02	Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration	MT

Press Releases

06-02	Telix and United Imaging Announce Strategic Theranostics Collaboration	AQ
06-01	ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026	AQ
06-01	Telix Pharmaceuticals : William Blair Growth Conference Presentation (7bff72)	PU
05-27	Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences	AQ
05-18	IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing	AQ
05-15	Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches	AQ
05-04	New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC	AQ
04-30	TLX101-Px (Pixlumi®) MAA Accepted in Europe	AQ
04-29	Unlocking the Potential of PSMA Therapy: A Next Generation Portfolio Approach (71df86)	PU
04-29	OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer	AQ
04-28	Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach	AQ
04-21	ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026	AQ
04-15	Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma	AQ
04-13	Telix Pharmaceuticals : and Regeneron Announce Strategic Radiopharma Collaboration	PU
04-09	FDA Accepts NDA for TLX101-Px (Pixclara®)	AQ
04-08	Telix Strengthens Board with Additional Director Appointments	AQ
04-06	Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement	PU
04-02	Telix Pharmaceuticals : Appoints David Gill as Non-Executive Director	PU
03-15	Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate	AQ
03-09	ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives	AQ
03-09	Telix Pharmaceuticals : ProstACT Global Part 1 Data (56a3ed)	PU
03-05	Future of Prostate Cancer Imaging: What do physicians want? (27083a)	PU
03-01	Investor Education Webinar	AQ
02-27	Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging	AQ
02-27	TLX591-Tx: Development overand data highlights (0388c8)	PU